Drug Profile
AZD 0837
Alternative Names: AR-H067637; AZD0837Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Thromboembolism
Most Recent Events
- 30 Jul 2010 Discontinued - Phase-II for Thromboembolism in European Union (PO)
- 14 Nov 2009 Adverse events and pharmacodynamics data from a phase II trial (NCT00623779) in Thromboembolism prevention presented at the the 82nd Annual Scientific Sessions of the American Heart Association
- 29 Aug 2009 Pharmacodynamics and pharmacokinetics data from a phase II trial in Atrial fibrillation presented at the Annual Congress of the European Society of Cardiology (ESC-2009)